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1. Introduction 
Parkinson’s disease (PD, OMIM entry #168600) is the most common progressive 
neurodegenerative disorder that not only affects a large group of individuals in Antioquia, 
Colombia (Pradilla et., 2003; Sanchez et al., 2004) but also affects other regions in the world. 
Actually, the prevalence of PD is between 0.1% and 0.3% in the general population and 
between 1% and 2% in persons 65 years of age or older (Alves et al., 2008). Moreover, the 
number of individuals with PD over age 50 has been projected between 8.7 and 9.3 million 
in Western countries by 2030 (Dorsey et al., 2007). PD is typified clinically by motor 
symptoms including bradykinesia, resting tremor, rigidity and gait posture abnormalities 
followed by postural instability and less frequent non-motor complication such as dementia, 
depression and autonomic dysfunction (Jancovic, 2008). Pathologically, the disorder is 
prominently characterized by progressive loss of 50–70% of dopaminergic neurons located 
in the substantia nigra, decrease of the neurotransmitter dopamine content in striatum 
(Forno, 1996), cytoplasmic inclusions of insoluble, aggregated proteins, including ǂ-
synuclein known as Lewy bodies (Cuervo et al., 2010), elevated levels and/or deposits of 
iron (Sian-Hülsmann et al., 2010) and selective neuronal vulnerability to oxidative stress 
(Wang & Michaelis, 2010). The cause of all cases of PD remains unknown. However, in the 
mid-1990s this situation changed with the identification of a mutation in the ǂ-synuclein 
gene associated with autosomal dominant PD in Italian kindred (Polymeropoulos et al., 
1997). Since then, more than 10 genes have been found either causal of the disease (e.g., 
Parkin, DJ-1, PTEN-induced putative kinase 1 (PINK-1), leucine rich region kinase 2 
(LRRK2), ATP13A2 (Xiromerisiou et al., 2010; Cookson, 2010; Hardy, 2010)) or as risk factor 
for PD (e.g.  HLA region). Interestingly, the first gene that causes autosomal recessive 
                                                 
1Drosophila melanogaster has misleadingly been known as the fruit fly. Strictly, “…real fruit 
flies,…attack unblemished fruit and in heavy infestations cause serious economic damage. In contrast, 
even if present in enormous numbers, D. melanogaster is innocuous and of no economic importance” 
(Green, MM. (2002). It really is not a fruit fly, Genetics 162: 1-3). It is therefore most adequate to name 
Drosophila melanogaster as just Drosophila melanogaster fly 
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juvenile Parkinsonism (AR-JP) was reported and named parkin in 1998 by Kitada and 
colleagues. AR-JP maps to the long arm of chromosome 6 (6q25.2-q27). The parkin gene is 
composed of 2,960 base pairs with a 1,395-base-pair open reading frame encoding for a 
protein of 465 amino acids with moderate similarity to ubiquitin at the amino terminus and 
a RING-finger motif at the carboxy terminus. The gene spans more than 500 kilobases and 
has 12 exons (Kitada et al., 1998). Subsequent studies have shown that parkin is a RING-
finger-containing protein identified as an E3 protein-ubiquitin ligase (Shimura et al., 2000), 
which is an integral component of the cytoplasmic ubiquitin/ proteosomal degradation 
pathway (Betarbet et al., 2005). The reaction promoted by E3 ligases is the addition of a 
lysine-linked chain four or more ubiquitin molecules to the target protein, which is 
recognised by the subunits in the proteosome. Thus, mutation of the parkin gene could result 
in accumulation of misfolded proteins (Tanaka et al., 2001; Imai and Takahashi, 2004). 
Therefore, it is hypothesized that mutations in parkin gene, which result in loss of function, are 
unable to remove enough mutated or misfolded proteins leading to nigral neurodegeneration. 
Moreover, the Parkin protein may play a role in promoting autophagy of dysfunctional 
mitochondria following loss of mitochondrial membrane potential (Bueler, 2010).   
Currently, AR-JP (OMIM entry #600116) is consider a distinct genetic entity characterised by 
early age at onset (<age 45), dystonia with parkinsonism and improvement of symptoms 
after sleep, slow disease progression, associated signs such as hyperflexia, dysautonomia, 
peripheral neuropathy and good response to low doses of L-DOPA (Zhang et al., 2001). 
Additionally, iron deposits are found in PD (Dexter et al., 1989; Sofic et al., 1991; Riederer et 
al., 1992; Griffiths et al., 1999) as well as in AR-JP (Takanashi et al., 2001). Why dopaminergic 
neurons in the substantia nigra are particularly vulnerable to the loss of parkin function and 
iron deposition is yet unknown. To date, the most common known form of hereditary 
Parkinsonism, i.e. AR-JP, diagnosed in Antioquia, Colombia is due to the parkin C212Y 
mutation. This mutation is a novel G to A transition in exon 6 at position 736 (G736A) of 
parkin gene. The C212Y mutation was identified in a genetic isolate community from two 
paisa family groups (PJF-1, PJF-3) by Pineda-Trujillo et al., (2001). Interestingly, the 
mutation was subsequently observed in a Spanish family, suggesting that it could have been 
taken to Antioquia by Spanish immigrants. Pineda-Trujillo et al., (2006) screened for the 
G736A mutation in additional Antioquian early onset PD cases and used haplotype analysis 
to investigate the relationship between Spanish and Antioquian G736A chromosomes. They 
confirmed the occurrence of an extensive founder effect in Antioquia. Thirteen individuals 
(10 homozygotes) from seven nuclear families were identified with the G736A mutation. 
Genealogical investigations demonstrated the existence of shared ancestors between six of 
these families four to five generations ago and no evidence of Spanish ancestry during this 
period. A second parkin mutation (a duplication of exon 3), was detected in the three G736A 
heterozygote carriers. Haplotype data exclude a recent common ancestry between the 
Spanish and Antioquian patients studied and are consistent with the introduction of the 
G736A mutation in Antioquia during early colonial times by about 16 generations ago. 
Further studies have also confirmed the presence of a GT insertion in exon 3 mutation 
among Paisa community previously identified in Spanish and French families with juvenile 
Parkinsonism (Pineda-Trujillo et al., 2001, 2009). Strikingly, the proteins that are reported to 
be related to familial PD such as PINK1, DJ-1, ǂ-synuclein, LRRK2 and possibly parkin are 
either mitochondrial proteins or are associated with mitochondria. Interestingly, all those 
proteins are involved in pathways that elicit oxidative stress or free radical damage (Lin et 
al., 2009).  
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Free radials are defined as any atom or molecule that has one or more unpaired electrons in 
its outer shell such as anion superoxide radical (.O2), hydroxyl radical (.OH),  nitric oxide 
(NO.) and their products (e.g. H2O2). Oxidative stress (OS) refers to a state in which free 
radicals are in excess of antioxidant defence mechanism (e. g. superoxide dismutase (SOD), 
glutathion peroxidase (GPx), catalase, vitamin C and E). As a result of this imbalance, the 
free radicals are capable of reacting with lipids, proteins, nucleic acids, and other molecules 
altering their structure and function. Accordingly, OS can lead to serious structural 
modifications in cells by excessive accumulation of oxidized products such as aldehydes 
and isoprostanes from lipid peroxidation, protein carbonyls from protein oxidation, and 
base adducts from DNA oxidation. Because the human brain is a high oxygen consumer 
organ, it is reasonable to assume that, under pathological conditions, it might be a target of 
permanent OS attack. 
Over the last two decade, OS has been proposed to play a critical role in the pathogenesis of 
PD (Fahn and Cohen, 1992; Jenner & Olanow, 1996; Tsang & Chung, 2009). In fact, several 
markers of OS have been identified in post-mortem brain tissues including increased levels 
of DNA and RNA oxidation (e.g. 8-hydroxyl-2-deoxyguanosine and 8-hydroxyl 
deoxyguanosine), protein carbonyl levels, glycation and glycoxidation, lipid peroxidation 
and high iron concentration (Zhou et al., 2008). Moreover, given that iron and DA generate 
reactive oxygen species (ROS), they have been implicated in the OS observed in PD 
(Asanuma et al., 2004). Not surprisingly, lymphocytes have been used to test for oxidative 
stress (Battisti et al., 2008) and cell death (Calopa et al., 2010) in PD. For instance, Migliore et 
al., (2002) has demonstrated an increase in the incidence of spontaneous micronuclei, single 
strand breaks and oxidized purine bases in PD patients without treatment. These results 
clearly showed oxidative DNA damage demonstrable in lymphocytes. Moreover, we found 
that homozygote Cys212Tyr parkin mutation in AR-JP patients renders lymphocytes 
sensitive to dopamine, iron and hydrogen peroxide stimuli (Jimenez-Del-Rio et al., 2004).  In 
agreement with these findings, Prigione and co-workers (2009) have shown increased 
oxidative stress in lymphocytes from untreated Parkinson's disease patients. Interestingly, 
Jiang et al., (2004) have shown that parkin protects human dopaminergic neuroblastoma 
cells against dopamine-induced cell death. Taken together these data suggest that analysis 
of DNA or lymphocytes response against oxidative stress might be used as an early marker 
of the OS status in PD patients.  
Despite these evidences, there are still major unresolved issues in the understanding of the 
molecular and cellular biology of PD. Indeed, a complete picture of the precise molecular 
cascade leading to cell death in a single cellular model in this disorder is still lacking. 
Therefore, we have been interested in investigating the oxidative stress phenomenon and 
apoptosis signalling in lymphocytes and Drosophila melanogaster. 
2. In vitro and In vivo models 
2.1 Human lymphocytes resemble neuronal cells 
The brain and the immune system are involved in functionally relevant cross–talk 
influencing one another's actions, whose main function is to maintain homeostasis. 
Therefore, to play such a role, lymphocytes are equipped with several biochemical systems 
that display comparable pathways to neural cells. This unusual characteristic makes 
lymphocytes an excellent in vitro model (Massaud et al., 1998; Kriesberg, 2011) to 
understand normal and abnormal function from gene to phenotype. Moreover, lymphocytes 
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might provide the basis of biochemical and cytopathological mechanisms for preventive or 
therapeutic intervention. These cells thus appear to be particularly fascinating cell model for 
PD at least for three main reasons. First, lymphocytes express six homologous 
neurochemical systems (Table). 
 
System Protein  Expression 
1. Dopaminergic 
Tyrosine hydroxylase & monoamine oxidase (Marino et al., 
1999 & references within); dopamine transporter (Amenta 
et al., 2001; Marazziti et al., 2010); dopamine D2-, D3-, D4-, 
D5-like receptors (Ricci & Amenta, 1994; Ricci et al., 1995, 
1997; Amenta et al., 1999; McKenna et al., 2002). 
2. Serotonergic 
Serotonin transporter (SERT, Faraj et al., 1991; Marazziti et 
al., 2010); serotonin receptors (Stefulj et al, 2000); 
tryptophan hydroxylase (Carrillo-Vico et al., 2004). 
3. Cholinergic 
Acetylcholine (Ach), muscarinic and nicotinic Ach 
receptors (mAChRs and nAChRs), choline acetyltransferase 
(ChAT), high affinity choline transporter and 
acetylcholinesterase (Kawashima & Fujii, 2004). 
4. Glutamatergic 
Ionotrophic glutamate receptors (Lombardi et al., 2001, 
2004); 
group I metabotropic glutamate receptors (Miglio et al., 
2005). 
5. Adrenergic -2 adrenergic receptors (Sanders, 1998). 
6. Gabaergic 
Ǆ-aminobutiric acid (GABA) receptors (Tillakaratne et al., 
1995). 
Table 1. Neuronal Molecular systems expressed in lymphocytes. 
Second, lymphocytes express similar molecular death machinery leading to typical 
morphologic and biochemical features of apoptosis. Apoptosis is a type of programmed cell 
death initially defined by Kerr and co-workers in 1972 and recently refined by several others 
(Kerr et al., 1995; Xu & Shi, 2007; Kroemer et al., 2009). Apoptosis is originally a 
morphological phenomenon characterised by chromatin condensation and nuclear 
fragmentation, plasma membrane blebbing, cell shrinkage and preservation of organelles 
such as mitochondria. These characteristics can be recognised in lymphocytes under 
fluorescent microscopy (Fig. 1) or electron microscopy (Sakahira et al., 1999; Marini et al., 
2001). Noticeably, what causes these morphological changes that we recognize as apoptosis 
occurs through multiple independent pathways that are initiated either from triggering 
events within the cell (i.e the “intrinsic pathway”) or from outside the cell (i.e. the “extrinsic 
pathway”). The “intrinsic pathway” involves the release of mitochondrial proteins such as 
cytochrome C, second mitochondrial-derived activator of caspase/direct IAP-associated 
binding protein with low PI (Smac/DIABLO), apoptosis inducing factor (AIF) and 
Endonuclease G (Endo G). The “extrinsic pathway” involves Fas/FasL pathway, caspase-8 
activation, bid degradation and releasing cytochrome C. Strikingly, both pathways converge 
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on a common machinery of cell dismantling executed by a family of cysteine proteases 
known as Caspases. Indeed, caspases cleavage at aspartate residues of targeted proteins 
(Chowdhury et al., 2008). Particularly, caspase-3 degrades the inhibitor of caspase-activated 
DNase (ICAD/ DNA fragmentation Factor-45, DFF-45) protein releasing the caspase-
activated DNase (CAD/ DFF-40) that result in DNA degradation (“DNA ladder pattern”) 
from mouse T-cell lymphoma (Enari et al., 1998; Sakahira et al. 1998), Jurkat T cells (Liu et al, 
1997) and HeLa cells (Halenbeck et al., 1998) under pro-apoptotic treatments. It is worth to 
mention that almost 18-years passed before an explanation could be drawn for one of the 
earliest well-recognized biochemical characteristics of apoptosis i.e. “DNA ladder pattern”, 
from the time when Wyllie reported glucocorticoid-induced thymocytes apoptosis 
associated with endonuclease activation (Wyllie, 1980). Unquestionably, morphological and 
biochemical data have helped considerably to enlighten, yet unsettled, the mechanism of 
neural cell death in PD (Levy et al., 2009). 
 
 
Fig. 1. Human lymphocytes treated with xenobiotic paraquat, PQ for 24h. Figure shows 
typical nuclear apoptotic morphology such as highly condensed chromatin (arrows) and 
nuclear fragmentation (arrowheads) from lymphocytes treated with PQ compared to normal 
nuclei (asterisk) stained with acridine orange/ ethidium bromide.  A similar apoptotic 
morphology can be observed with dopamine, DA; 6-hydroxydopamine, 6-OHDA; 5,6 & 5,6 
dihydroxydopamine, 5,6 & 5,7-DHT; rotenone, ROT. Jimenez-Del-Rio & Velez-Pardo, 2008. 
Reproduced with permission from Informa Healtcare UK Ltd. 
Third, lymphocytes and neurons are post-mitotic cells, i.e. they become locked in a G0 phase 
of the cell cycle. This is a remarkable biological feature to be cautiously considered when 
interpreting experimental data since evidence has accumulated that a cell division forced on 
a mature neuron leads to apoptosis rather than division (Herrup et al., 2004), but cell 
division is induced in lymphocytes. In other words, the use of cell lines instead of primary 
cultures could be confusing and /or misleading. For instance, NF-κB is a transcriptional 
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factor composed of a p50/p65 heterodimer protein that upon activation binds to specific 
DNA sequences in target genes, designated as κB-elements. This factor is involved in both 
cell cycle-regulation and cell death processes. In dividing cells, NF-κB transcribes cyclin D1, 
which in association with cyclin-dependent kinases, CDK4 and CDK6, promotes G1/S 
phase transition through CDK-dependent phosphorilation of retinoblastoma protein (pRb), 
thereby releasing the transcription factor E2F, required from the activation of S phase-
specific genes. Indeed, constitutive activation of NF-κB is intimately intertwined with cancer 
growth and metastasis (Prasad et al., 2010). On the other hand, the regulatory roles of NF-κB 
on apoptosis suggest that NF-κB is acting on the upstream pathways of apoptosis, either 
negatively or positively (Shishodia & Aggarwal, 2004; Qin et al., 2007). Noticeably, in non-
dividing cells, these confounding matters connected with the role of NF-κB in apoptosis and 
cell-cycle control might not be an important issue given that NF-κB function can eventually 
be studied independently from the cell cycle function. Thus, G0 represents not simply the 
absence of signals for mitosis but an active repression of the genes needed for mitosis.  
2.1.1 Human lymphocytes as cellular model to study oxidative stress and apoptosis in 
PD. 
Deciphering the Parkinson’s disease cascade(s) is one of the ultimate research goals in the 
PD field not only because it offers the possibility to scrutinize a basic cellular machinery of 
response to different deleterious stimuli, but also because it brings the possibility to predict 
novel therapies. Accordingly, we postulated a unified molecular cascade model wherein 
H2O2 is definitely a paramount molecule involved in intracellular signalisation that induces 
neuronal loss in PD (Jimenez-Del-Rio & Velez-Pardo, 2000, 2004a & Fig. 2). Effectively, we 
were able to clarify the major signalling events by which DA (Jimenez-Del-Rio et al., 2004), 
monoamine related toxins (e.g. 6-OHDA; 5,6-DHT; 5,7-DHT: Jimenez-Del-Rio & Velez-
Pardo, 2002), redox metals such as Fe2+, Cu2+, Mn2+, Zn2+ (Jimenez-Del-Rio & Velez-Pardo, 
2004b & Fig. 3) and H2O2 (Jimenez-Del-Rio & Velez-Pardo, 2006) might induced cell death in 
normal and/or mutated lymphocytes (e. g. C212Y in parkin) PD.  
During the last few years, several reports have been published supporting our findings. 
Liang et al., (2007) have found that NF-B contributes to 6-OHDA-induced apoptosis of 
nigral dopaminergic neurons through p53. Bernstein and co-worker (2011) have shown that 
6-OHDA generated ROS induces DNA damage and p53- and PUMA-dependent cell death. 
Bilobalide, which is a constituent of Ginkgo biloba 761, inhibits 6-OHDA-induced activation 
of NF-B and loss of dopaminergic neurons in rat substantia nigra (Li et al., 2008). 
Importantly, Aleyasin et al., (2004) have shown that acute inhibition of NF-B via expression 
of a stable IB mutant, down-regulation of the p65 NF-B subunit by RNA interference 
(RNAi), or pharmacological NF-B inhibitors significantly protected against DNA damage-
induced neuronal death. NF-B inhibition also reduced p53 transcripts and p53 activity as 
measured by the p53-inducible messages, Puma and Noxa, implicating the p53 tumor 
suppressor in the mechanism of NF-B-mediated neuronal death.  Takada et al. (2003) have 
shown that H2O2 activates NF-kappa B through tyrosine phosphorylation of IB and serine 
phosphorylation of p65 by IB kinase and Syk protein-tyrosine kinase. Prabhakaran et al., 
(2008) have shown that NF-B induction and the activation of nitric oxide synthase through 
ROS represents a proximate mechanism for Mn-induced neurotoxicity. Therefore, we 
conclude that NF-B, p53 and caspase-3 are crucial signalling molecules involved in H2O2-
induced cell death. Based on this model, we predicted that molecules capable of generating 
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Fig. 2. Schematic model of dopaminergic and serotonergic related toxins-induced 
apoptosis by an oxidative stress mechanism in PBL. 6-OHDA; 5,6-& 5,7-DHT or protein 
fragment A generate H2O2. This last compound might activates JNK/SAPK kinases 
pathway, which in turn activate in parallel both NF-κB and c-Jun transcription factors. NF-
κB is able to activate the transcriptional factor p53 and subsequently it may activate the pro-
apoptotic Bax protein, which induces cytochrome C release from mitochondria to activate 
the apoptosome complex leading to caspase-3 activation and apoptosis. Jimenez Del Rio and 
Velez-Pardo, 2002. Reproduced with permission from Elsevier.  
H2O2 might induce a mechanism resembling the one depicted in Fig. 2. To further test our 
model, we used paraquat (PQ), also known as methyl viologen dichloride or 1,1’-dimethyl-
4,4’-bipyridinium dichloride, and rotenone (ROT), a redox cycling herbicide and a 
mitochondrial complex I inhibitor as xenobiotic compound generally used to model PD 
(Bové et al., 2005). We concluded that both PQ-and ROT-induced time- and concentration-
dependent apoptosis in lymphocytes which was mediated by anion superoxide radicals 
(O2)) ⁄ hydrogen peroxide, depolarization of mitochondria, caspase-3 activation, 
concomitantly with the nuclear translocation of transcription factors such as NF-B, p53, c-
Jun and nuclei fragmentation (Fig. 4-5, Jimenez-Del-Rio & Velez-Pardo, 2008; Avila-Gomez 
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Fig. 3. Schematic representation of the major molecular events induced by metals in 
lymphocytes. Fe2+-metal ions in the presence of molecular dioxygen (1) generate superoxide 
radicals (2), which dismutate either by enzymatic (e.g., superoxide dismutase, SOD) or 
spontaneously into H2O2 (3). This last compound in turn may react with Fe2+ to produce 
hydroxyl radicals (4) (OH·) by Fenton reaction. Over-production of (OH·) may alter the 
mitochondria transmembrane potential (5) inducing the liberation of different apoptogenic 
factors and subsequent activation of caspase-3 (6) resulting in disassembly and 
fragmentation of nuclear chromatin leading PBL to apoptosis (7). The symbol (   ) represents 
the inhibition (by indicated compound) of the critical steps of the molecular cascade leading 
to apoptosis by metal ions. Jimenez-Del-Rio & Velez-Pardo, 2004b. Reproduced with 
permission from Elsevier.    
et al., 2010). Interestingly, Choi et al., (2010) have shown that JNK3 mediates PQ- and ROT-
induced dopaminergic neuron death. Remarkably, the cell death routine depicted in Fig. 3 
can be reversed by the action of cannabinoids (Jimenez-Del-Rio & Velez-Pardo, 2008), IGF-1 
(Avila-Gomez et al., 2010) and glucose (Jimenez-Del-Rio & Velez-Pardo, 2008; Avila-Gomez 
et al., 2010). These data may provide innovating therapeutic strategies to intervene 
environmentally or genetically susceptible PD population to oxidative stress.  
2.1.2 Alternative therapies for parkinson’s diseases: a mechanistic igf-1, 
cannabinoids and glucose proposal 
Based on recent progress in delineating the disease cascade and cell death process (Jenner & 
Olanow, 1998; Blum et al., 2001; Wirths et al., 2004; Jimenez-Del-Rio & Velez-Pardo; 2004a; 
Green & Kroemer, 2005; Przedborski, 2005; Jimenez-Del-Rio & Velez-Pardo, 2008; Avila-
Gomez et al., 2010), discrete types of potentially disease modifying treatment could be 
administered for PD. In this regard, our data have highlighted the potential use of 
lymphocytes as a model to screen antioxidant strategies designed to remove 
(Fe2+)/(O2.)/(H2O2)/(OH.), signalling inhibitors and/or restorative approaches as promising 
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Fig. 4. Schematic model of the major molecular events induced by PQ in lymphocytes. 
PQ in the presence of NADH/NADPH reductases (1) is converted into monocationic radical 
compound which readily react with molecular dioxygen to generate superoxide radicals (2), 
which dismutase either by enzymatic (e.g. superoxide dismutase, SOD) or spontaneously 
into H2O2 (3) This last compound in turn may activate the mitogen-activated protein kinase 
kinase kinase (e.g. MEKK1) which can activate both c-Jun (4) via activation of MKK4/JNK, 
and NF-B activation (5) via phosphorylation of the IBa (i.e. the repressor of NF-B) by the 
IKK complex. The NF-B translocates into the nucleus and transcribes p53 protein (6). 
Consequently, this protein transcribes pro-apoptotic proteins (e.g. Bax) which are able to 
permeabilize mitochondria, thus, promoting the activation of caspase-3 (7) which signals 
chromatin fragmentation, typical of apoptotic morphology (8). The symbol (    ) represents 
the inhibition (by indicated compound) of the critical step of the molecular cascade leading 
to apoptosis by PQ. Jimenez Del Rio & Velez-Pardo, 2008.  Reproduced with permission 
from Informa Healtcare UK Ltd.  
www.intechopen.com
 Mechanisms in Parkinson’s Disease – Models and Treatments 
 
416 
 
Fig. 5. PQ induces simultaneous activation of the transcription factors in lymphocytes. PBL 
cells were left untreated (A–C) or exposed to 1mMPQ (D–F) for 24 h. After this time of 
incubation, cells were stained with anti-NF-B-p65 (A and D), anti-p53 (B and E) and anti-c-
Jun (C and F) antibodies according to procedure described in Materials and methods. Notice 
that NF-B, p53 and c-Jun positive-nuclei (dark brown color) reflect their nuclear 
translocation/activation and appear to correlate with the apoptotic nuclear morphology, i.e. 
condensed/fragmented nuclei when compared with untreated cells (A–C). Magnification 
400 x (A–F). Jimenez-Del-Rio & Velez-Pardo, 2008.  Reproduced with permission from 
Informa Healtcare UK Ltd. 
therapy for PD. As depicted in Figs. 2-4, these mechanistic pathways may be of potential use 
for screening pharmacologically chemical libraries containing hundreds to thousands of 
compounds each that could modulate or control sensible molecules critical in cell fate (e. g., 
H2O2, NF-κB, p53, c-Jun, caspases). Recently, neurotrophic factors have come into focus as 
potential therapy in PD (Evans et al., 2008). One clue of its neuroprotective capability comes 
from the fact that IGF-1 is able to activate NF-κB against H2O2 oxidative stress (Heck et al., 
1999). However, it has also been shown that NF-κB activation is involved in H2O2-induced 
apoptosis (Kutuk & Basaga, 2003). Therefore, the molecular mechanism(s) that explain the 
dual role of NF-κB as attenuator or promoter of apoptosis and the IGF-1’s molecular 
mechanism of neuroprotection still remain to be established.  
Taken advantage of the fact that human PBL express IGF-1 receptors (Tapson et al., 1988; 
Kooijman et al., 1992) and IGF-1 appears to be of potential therapeutic use against PD 
(Quesada et al., 2008), we were interested in the understanding of the molecular events that 
are thought to be downstream of IGF-1, in relation to the role played by NF-κB in survival 
and death-signalisation against PQ, ROT and H2O2 in lymphocytes, as a single cell model. 
We found that (100 nM) IGF-1 protects lymphocytes from (1 mM) PQ, (250 M) ROT and 
(25, 50, 100μM) H2O2-induced apoptosis through NF-κB activation and p53 down regulation 
involving the phosphoinositide 3-kinase (PI-3K)–dependent pathway. Interestingly, IGF-1, 
PDTC (a NF-κB inhibitor) and pifithrin-ǂ (PFT, a p53 inhibitor) were able to protect and 
rescue lymphocytes pre-exposed to PQ even when the three compounds were added up-to 6 
h post-PQ exposure. Overall these observations suggest that survival and rescue of 
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lymphocytes from PQ and ROT toxicity is determined by p53 inactivation via IGF-1/ PI-3K 
pathway (Jimenez Del Rio & Velez-Pardo, 2008; Avila-Gomez et al., 2010).  
Which molecular mechanism(s) explain the dual role of NF-κB as an attenuator or promoter 
of apoptosis? NF-κB has been reported to activate both pro-apoptotic genes such as p53 
transcription factor (Wu & Lozano, 1994; Hellin et al., 1998; Jimenez Del Rio & Velez-Pardo, 
2002; Velez-Pardo et al., 2002; Aleyasin et al., 2004), which in turn activates the expression of 
several genes that directly control or regulate the process of apoptosis such as Bax, which is 
a pro-apoptotic Bcl-2 protein family (Xiang et al., 1998), and anti-apoptotic genes such as 
Bcl-2, Bcl-XL, X-linked inhibitor of apoptosis (Kairisalo et al., 2009). Therefore, one prevailing 
model proposes that when the molecular ratio of pro-survival (e.g. Bcl-2, Bcl-xL, Bcl-w) to 
pro-death Bcl-2 family members (e.g. Bax, Bad, Bak, Bid) is biased towards pro-death Bcl-2 
family members either through changes in expression level, localization or activity, the 
outer mitochondrial membrane becomes permeable to apoptogenic proteins resulting in the 
activation of a cascade of effector caspases, such as caspase-3, that kill the cells by 
irreversible proteolysis of critical nuclear and cytoplasmic constituents. In this vein, our data 
suggest that IGF-1 might promote gene transcription of survival genes via NF-κB activation 
(Kane et al., 1999) and suppresses gene transcription of pro-apoptotic proteins through p53 
inactivation. How then p53 turn-off could be related with IGF-1 citoprotection? One possible 
explanation for this phenomenon comes from the work by Ogawara and colleagues (2002) 
who showed that Akt enhances the ubiquitinization-promoting function of Mdm2 (murine 
double minute) by phosphorylation of S186, which results in reduction of p53 protein. 
Furthermore, Feng and colleagues (2004) showed that PKB/Akt induces phosphorylation of 
Mdm2 at Ser166 and Ser188 resulting in Mdm2 protein stabilization. Based on this information 
and our data, it is reasonable to assume that p53 is modulated by IGF-1 through PI3K-Akt 
pathway. In fact, our findings reveal that p53 but not NF-κB is the critical transcription 
factor that may possibly balances the expression of pro-death proteins towards intracellular 
death decision under oxidative noxious stimuli (Lu, 2005). Therefore, an ideal natural or 
synthetic pharmacological compound would be one that efficiently function as an 
antioxidant (e.g. 17ǃ-estradiol (Jimenez-Del-Rio & Velez-Pardo, 2001; vitamin E) and 
simultaneously act as a survival signalling molecule (e.g. IGF-1). To our surprise, the 
molecules exhibiting both features might come from the glandular hairs of Cannabis sativa or 
marijuana, actually known as cannabinoids.  
2.1.2.1 Cannabinoids 
Cannabinoids are a group of C21 terpenophenolic compounds (Elsohly & Slade, 2005), which 
exert their effects by binding to specific plasma membrane G-protein-couple receptors, 
termed CB1 (Matsuda et al., 1990) and CB2 (Munro et al., 1993) receptors. Activation of these 
receptors has been shown to trigger several Gi/o-protein-mediated signalling pathways 
(Turu & Hunyady, 2010). Although, it is currently accepted that CB1 receptors are specially 
abundant in basal ganglia, hippocampus, cerebellum and cortical structures; and CB2  
receptors are restricted to cell types related to the immune function such as  spleen 
macrophages, tonsils, B cells and natural killer cells, monocytes, neutrophils, and T cells 
(Pazos et al., 2005), it has also been demonstrated the existence of CB2 receptors in purkinje 
cerebellar neurons (Skaper et al., 1996), microglia (Klegeris et al., 2003), oligodendrocytes 
(Molina-Holgado et al., 2002) and brainstem neurons (Van Sickle et al., 2005). Moreover, 
both receptors elicit similar signalling pathways such as inhibition of adenylate cyclase, 
stimulation of extracellular-signal-regulated kinase (Demuth & Molleman, 2006) and 
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activation of phosphoinositide 3-kinase/PKB (Gomez Del Pulgar et al., 2000; 2002; Molina-
Holgado et al., 2002; Sanchez MG et al., 2003). The physiological significance of these 
common characteristics is still unknown. 
Cannabinoids have been proposed as potential therapeutic agents against PD (García-
Arencibia et al., 2009) thanks to their involvement in control of cell death/ survival decision 
and in neuroprotection (van der Stelt & Di Marzo, 2005). However, the mechanism of both 
actions by cannabinoids is far from clear. Moreover, cannabinoids have been shown to 
function as antioxidant compounds via receptor-independent (Hampson et al., 1998; Chen et 
al., 2000; Marsicano et al., 2002) or receptor-dependent mechanisms (Nagayama et al., 1999; 
Kim et al., 2005) or both mechanisms (Kaplan et al., 2003). Although CB antagonists (v. gr. 
SR141716A) have been used to elucidate the neuroprotective mechanism of cannabinoids, 
they have not been conclusive (see Marsicano et al., 2002 versus Nagayama et al., 1999; Kim 
et al., 2005). Therefore, the molecular mechanism(s) of cannabinoids effect on cells is a 
complex and still controversial issue.  
Despite intense investigation, the detailed intracellular mechanism(s) involved in 
cannabinoids survival effect remains to be elucidated. Because CB2 cannabinoid receptor is 
linked to activation of PI3K (Sanchez MG et al., 2003), and the non-classical cannabinoid (-)-
CP55,940 (a CB1 and CB2 agonist) and JWH-015 (a CB2 agonist) are commercially available,  
we wanted to elucidate the molecular signalling downstream of CB2 receptor linked to the 
role played by NF-κB and p53 in survival and death-signalisation against oxidative stress 
stimuli. We found that both synthetic agonists protect and rescue PBL against A25-35- and 
PQ-induced apoptosis by receptor-independent and receptor-dependent pathway (Velez-
Pardo & Jimenez-Del-Rio, 2006; Jimenez Del Rio & Velez-Pardo, 2008). In agreement with 
our previous observations with IGF-1, these results suggest that CP55,940 /(JWH-015) 
protective and rescue effect on PBL from noxious stimuli is determined by p53 inactivation.  
Recently, we investigated the ability of CP55,940 and JWH-015 to scavenge reactive oxygen 
species and their effect on mitochondria permeability transition (MPT) in either a 
mitochondria-free superoxide anion generation system, intact rat brain mitochondria or in 
sub-mitochondrial particles (SMP) treated with PQ. Oxygen consumption, mitochondrial 
membrane potential (m) and MPT were determined as parameters of mitochondrial 
function. It was found that both cannabinoids effectively attenuate mitochondrial damage 
against PQ-induced oxidative stress by scavenging anion superoxide radical (O2-) and 
hydrogen peroxide (H2O2), maintaining m and by avoiding Ca2+-induced mitochondrial 
swelling (Velez-Pardo et al., 2010). Understanding the mechanistic action of cannabinoids on 
mitochondria might provide new insights into more effective therapeutic approaches for 
oxidative stress related disorders (Fig. 6).  Further investigation is needed to classify 
cannabinoids molecules (Padgett, 2005; Thakur et al., 2005) with effective anti-oxidant from 
those with pro-oxidant actions.  
2.1.2.2 Glucose 
Glucose is a soluble sugar added to all cell culture media. In fact, glucose entry to the cell is 
facilitated by glucose transporters (GLUTs 1-13) (Manolescu et al., 2007) and depending on 
cell type, the amount of glucose in cell culture formulations ranges from 1 g/L (5.5 mM) to 
as high as 10 g/L (55 mM). This is an important consideration to take into account because 
the same processes that can affect cells and molecules in vitro can occur in vivo. Lymphocytes 
are ideal for learning about glucose metabolism and resistance against oxidative stress for 
several reasons. First, these cells express GLU-1 and GLU-3 transporter proteins 
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Fig. 6. Scheme of proposed cannabinoid mechanism of action against Paraquat-induced 
mitochondrial oxidative stress. High mitochondrial membrane potential (m) in intact rat 
brain mitochondria drives PQ compound into the mitochondrial matrix. Once inside, (1) PQ 
is reduced to the monocation radical PQ-  at complex I in the respiratory chain by electrons 
donated from NADH. PQ- reacts rapidly with O2 to produce superoxide (O2-), thereby 
consuming high amount of oxygen. In turn, the (O2-) is enzymatically dismutated by 
MnSOD into H2O2. Then, H2O2 induces mitochondrial permeability transition pore (MPT) 
and decreases m. Interestingly, when cannabinoids are present (2), they can remove both 
O2- and H2O2 thereby blocking further ROS signaling. Most interestingly, cannabinoids 
inhibit MPT probably through interactions with the cyclosporine A-binding cyclophilin-D 
protein (black circle). As a result, cannabinoids maintain the MPT-multiprotein complex 
(MPC) in a close-stated, high (m) but O2 consumption is still high. Taken in conjunction 
these actions, cannabinoids thus protect mitochondria from further damage. Velez-Pardo et 
al., 2010. Reproduced with permission from Springer Publishers Ltd. 
(Piatkiewicz et al., 2007). Second, glucose metabolism in lymphocytes is a regulated process. 
Indeed, glucose can enter glycolytic, pentose phosphate and Krebs cycle pathways (Maciver 
et al., 2008). Therefore, these cells represent a remarkable non-neural cell model to 
understanding metabolic regulation of apoptosis and cell survival signaling against stressful 
stimuli.  
Previously, we have demonstrated that PQ- and ROT-induce apoptosis in lymphocytes 
cultured in standard RPMI 1640 culture medium, which contains 11 mM glucose (11G), via a 
cascade of molecular events involving O2.- and H2O2, as prime death signals (Jimenez-De-
Rio & Velez-Pardo, 2008; Avila-Gomez et al., 2010). Interestingly, by increasing the 
concentration of glucose to 55 mM (55G) in RPMI 1640 culture medium, it has been shown 
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that glucose almost completely protected lymphocytes against PQ-and ROT-induced 
apoptotic cell death (Jimenez-De-Rio & Velez-Pardo, 2008; Avila-Gomez et al., 2010). These 
data thus suggest that the predominance of PQ- and ROT-induced oxidative stress damage 
may be adjusted by decreasing or increasing the concentration of glucose in the cell culture 
media. By using biochemical analysis and pharmacological inhibition, we found that 55G 
was effective in suppressing rotenone-induced apoptosis in lymphocytes via four acting 
pathways which involve the pentose phosphate pathway (PPP-II), glutathione pathway, 
SOD and CAT antioxidant system and PI3-K signalling. Moreover, it is shown for the first 
time that glucose induced lymphocyte survival by NF-B activation and down-regulation of 
p53 and caspase-3 (Bonilla-Ramirez, L., Jimenez-De-Rio, M. & Velez-Pardo, C. (2011). 
Unpublished observations). Taken altogether these results suggest that antioxidants (e.g. 
cannabinoids), growth factors (e.g. IGF-1) and environmental factor (e.g. glucose) might 
regulate cell death in lymphocytes upon oxidative stress.  Unfortunately, lymphocytes as in 
vitro model of PD do not provide information about executive functions (i.e. cognitive 
process), kinesthesia (i.e. physical movement) and/or diet-related to PD. To further study 
the effect of xenotoxicity, diet and movement alterations, we therefore turn out our attention 
to Drosophila melanogaster.  
2.2 Drosophila melanogaster: an unexpected invertebrate in scene 
During the last few years, Drosophila melanogaster has been recognized as a valuable model 
to study neurodegenerative diseases (Lu, 2009; Hirth, 2010), especially PD (Botella et al., 
2009; Guo, 2010; Whitworth, 2011) for three main reasons. First, some genes implicated as 
causative of PD have at least one homolog in the fly (e.g. parkin, DJ-1, PINK::see 
htpp://superfly.ucsd.edu for further information). This unique feature has facilitated the 
functional interpretation of these genes in the human (Park et al., 2009; Bayersdorfer et al., 
2010). Second, the expression of PD related genes in Drosophila can be performed by using 
the binary GAL-4-dependent upstream activating sequence (GAL4/UAS) system (Phelps & 
Brand, 1998), thus providing an excellent tool to express pathological proteins in the fly´s 
brain (e.g. -synuclein, Feany & Bender, 2000). Third, the dopaminergic system of the fly is 
well characterised (Mao & Davis, 2009; White et al., 2010). Furthermore, comparable to the 
human condition, the Drosophila DA system is also involved in locomotor control 
(Riemensperger et al., 2011). Therefore, the similarity between the dopaminergic network, 
mode of drug action and behaviour in D. melanogaster and mammalian systems, has made 
the fly a very attractive model for anti-parkinsonism drug discovery (Whitworth et al., 
2006). Additionally, Drosophila offers the power of rapid drug screening (Pendleton et al., 
2002a; Faust et al., 2009). Amazingly, a variety of approaches have been used to model 
Parkinson’s-like motor dysfunction in Drosophila, including specific genetic alterations 
(Feany & Bender, 2000; Pendleton et al., 2002b; Wang et al., 2007; Sang et al., 2007); 
pharmacological inhibition of crucial proteins in the dopamine system (Pendleton et al., 
2002 a, b) or pharmacological  insult (Coulom et al., 2004; Chaudhuri et al., 2007). Indeed, 
previous studies have demonstrated that paraquat (PQ) induces selective cell death of 
dopaminergic neurons (Chaudhuri et al., 2007) through interaction with complex I of the 
mitochondrial respiratory chain (Cocheme & Murphy, 2008) and oxidative stress (Bonilla et 
al., 2006).  Therefore, on the understanding that the causes of PD are mainly oxidative stress 
and mitochondrial dysfunction, antioxidants, free radical scavengers, monoamine oxidase 
inhibitors, iron-chelators, and other such drugs are expected to be used. The study of 
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antioxidants is becoming one of the most important subjects in PD research. Based on our in 
vitro data, we investigated the effect of cannabinoids and polyphenols, which are defined as 
a group of chemical substances present in plants, fruits and vegetables characterized by the 
presence of one or more than one phenol unit per molecule with several hydroxyl groups on 
aromatic rings, in Drosophila melanogaster against PQ-induced oxidative stress.  
Recently, we have shown for the first time that CP55,940, a non-selective CB1/CB2 
cannabinoid receptor agonist, significantly protects and rescues Drosophila against PQ 
toxicity via a receptor-independent mechanism (Fig. 7). Interestingly, CP55,940 restores the 
negative geotaxis activity (i.e., climbing capability) of the fly exposed to PQ. Moreover, 
Drosophila fed with (1–200 M) SP600125, a specific inhibitor of the stress responsive Jun-N-
terminal kinase (JNK) signalling, and 20 mM PQ increased survival percentage and 
movement function (i.e., climbing capability) when compared to flies only treated with PQ. 
Taken together our results suggest that exogenous antioxidant cannabinoids can protect 
against and rescue from locomotor dysfunction in wild type (Canton-S) Drosophila exposed 
to stress stimuli (Jimenez-Del-Rio et al., 2008). Therefore, cannabinoids may offer promising 
avenues for the design of molecules to prevent, delay, or ameliorate the treatment of 
population at high risk of suffering Parkinson disease. 
Polyphenols are a group of chemical substances found in plants classified according to their 
chemical structural as (i) phenolic acids such as gallic (GA), caffeic (CA), coumaric (CouA), 
ferulic acid (FA), propyl gallate (PG); (ii) flavonoids, which are the largest group of 
polyphenols, and (iii) non-flavonoid polyphenols. Flavonoids involve anthocyanins and 
anthoxantins. The latter group is divided into flavonols, flavans, flavanols such as 
epicatechin (EC), epigallocatechin (EGC) and epigallocatechin-3-gallate (EGCG), flavones 
and isoflavones (D’Archivio et al., 2007). Numerous studies in the past decade have shown 
that polyphenols have in vitro and in vivo activity by preventing or reducing the deleterious 
effects of ROS associated with oxidative stress and neurodegeneration not only because of 
their strong antioxidant and metal-chelating properties (Sestili  et al., 2002; Melidou et al., 
2005;  Perron & Brumaghim, 2009), but also because of their capability to induce 
intracellular signalling pathways associated with cell survival and gene expression 
(Ramassamy, 2006; Zaveri, 2006). We demonstrated for the first time that pure polyphenols 
GA, FA, CA, CouA, PG, EC, EGC, and EGCG protect, rescue and, most importantly, restore 
the impaired movement activity (i.e., climbing capability) induced by paraquat in Drosophila 
melanogaster (Fig. 8). We also showed for the first time that high concentrations of iron (e.g. 
15 mM FeSO4) were able to diminish fly survival and movement to a similar extent as (20 
mM) paraquat treatment. Moreover, paraquat and iron synergistically affect both survival 
and locomotor function. Remarkably, propyl gallate and epigallocatechin gallate protected 
and maintained movement abilities in flies co-treated with paraquat and iron. Our findings 
indicate that pure polyphenols might be potent neuroprotective agents for the treatment of 
PD against stressful stimuli (Jimenez-Del-Rio et al., 2010). 
It is generally accepted that the causes of PD are mainly oxidative stress, abnormal protein 
aggregation and mitochondrial dysfunction. Furthermore, substantial evidence suggests 
diet (Chen et al., 2007) and environmental risk factors such as pesticides (Dick  et al., 2007) 
and heavy metals (Jones & Miller, 2008), in particular iron intake (Logroscino et al., 2008), as 
causative of PD. However, how genetic and environmental factors are related to the 
nutritional status of PD patients is still unknown. Moreover, it has not yet been definitively 
established whether the nutritional status of PD patients might contribute to the 
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Fig. 7. Protective effect of antioxidants in Drosophila m. exposed to paraquat. 
Female flies were pre-fed with either 1% glucose alone, 0.5 mM CP55,940 or 0.5 mM vitamin 
E with 1% glucose in dW for 72 h. Then, flies were left untreated (GLU) or treated with 20 
mMparaquat (PQ; vit E + PQ; CP + PQ) for 6, 12, 24 and 48 h. (A) Survival rate (%) and (B) 
locomotion assay were recorded at the indicated time. *p < 0.05, **p < 0.001. Jimenez-Del-
Rio et al., 2008. Reproduced with permission from Elsevier.  
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Fig. 8. Protective effect of polyphenols in D. melanogaster exposed to paraquat. 
(A) Female flies were pre-fed with either 1% glucose alone or with 0.1 mM gallic acid (GA), 
ferulic acid (FA), caffeic acid (CA), coumaric acid (CouA), propyl gallate (PG), epicatecin 
(EC), epigallocatechin (EGC), epigallocatechin gallate (EGCG) polyphenols and  0.1 mg/ml 
Stalevo® with 1% glucose in distilled water (dW) for 72 h. Then, flies were left untreated (U) 
or treated with 20mM paraquat (PQ) for 24 and 48 h. Survival rate (%) and (B) locomotion 
assay were recorded at the indicated time.  *p<0.05, ** p<0.001. Jimenez-Del-Rio et al., 2010. 
Reproduced with permission from Elsevier.  
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development of the disorder. Therefore, we investigated the effect of glucose in Drosophila 
melanogaster under oxidative stress stimuli.   
We have shown that female D. melanogaster fed acutely with 20mM PQ in high concentration 
of glucose (e.g. 10%), as the sole energetic source, not only prolonged survival but also the 
locomotor activity remained unaltered when compared to fly fed with low concentration of 
glucose (e.g. 1%) and PQ over a period of 24-48 h (Fig. 9). Additionally, we found that 
polyphenols protect, rescue and restore the impaired movement activity in Drosophila induced 
by 20 mM PQ in 1% glucose for 24 h exposure (Fig. 8). We also showed that high 
concentrations of iron (e.g. 10-20 mM FeSO4) were able to diminish fly survival and locomotor 
activity over a period of 120 h (5 days). Taken together these findings suggest that either 
glucose or polyphenols might modulate life span and movement capabilities in D. melanogaster 
exposed to PQ and iron in short time frame. Since there is compelling evidence that shows that 
the pre-clinical period of PD extends at least 20 years before the motor manifestations (Savica 
et al., 2010), it is necessary to establish a close parallel with the fly to better understand 
antioxidant therapy approaches over long period of time. Therefore, we studied the life span 
and locomotor activity (i.e. climbing capability) of D. melanogaster chronically exposed to 
increasing concentrations of PQ and iron alone or in combination upon 1% or 10% glucose 
feeding regimen for 15 days and determined whether polyphenols such as GA, PG, EC and 
EGCG affect the life span and locomotor activity of the fly exposed to PQ for 15 days. It is 
known that protein aggregation is associated to PD (Tan et al., 2009). Interestingly, high 
expression levels of the transcription GAL4 protein in D. melanogaster have been shown to 
result in reduced life span (Haywood et al., 2002). Therefore, by using Ddc-GAL4 Drosophila 
melanogaster line, we also investigated whether genetically altered Ddc-GAL4 flies renders them 
sensitive to PQ-induced oxidative stress and whether glucose and polyphenols might 
modulate life span and/or locomotor activity in this line of Drosophila melanogaster. 
 
 
Fig. 9. Effect of glucose concentration in Drosophila m. exposed to paraquat.  
Male (M) and female (F) were either pre-fed with 1, 5 or 10% glucose (GLU) in distilled 
water for 72 h. Then, flies were treated with 20 mM paraquat (PQ) for 24 and 48 h. Survival 
rate (%) weas recorded at the indicated time. *p < 0.05, **p < 0.001. Jimenez-Del-Rio et a., 
2008. Reproduced with permission from Elsevier.  
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We found for the first time that polyphenols exposure prolong life span (P<0.05 by log-rang 
test) and restore locomotor activity (i.e., climbing capability, P<0.05 by 2 test) of Drosophila 
melanogaster chronically exposed to paraquat compared to flies treated with paraquat alone 
in 1% glucose (Fig. 10). We found that (10%) glucose partially prolongs life span and 
climbing in Drosophila exposed to iron, PQ or in combination, suggesting that both stimuli 
enhance a movement disorder in a concentration-dependent and temporal-related fashion. 
Moreover, chronic exposure of (1 mM) PQ/ (0.5 mM) iron synergistically affect both 
survival and locomotor function independently of the temporal order of the exposure to the 
toxicants, but the survival is modulated in a concentration and temporal fashion by glucose. 
This investigation is the first to report that Ddc-GAL4 transgenic flies chronically fed with 
polyphenols increase life span (P<0.05 by log-rang test) and enhance movement abilities 
(P<0.05 by 2 test) compared to untreated Ddc-GAL4 or treated with paraquat in 1% glucose. 
Our present findings support the notion that Drosophila melanogaster might be a suitable 
model to study genetic, environmental and nutritional factors as causal and/or modulators 
in the development of PD. Most importantly, according to our model, we have 
demonstrated for the first time chronic polyphenols exposure as potential therapeutic 
compounds in the treatment of PD. These findings altogether open new avenues for the 
screening, testing and development of novel antioxidant drugs against oxidative stress 
stimuli (Ortega-Arellano et al., 2011). 
3. Conclusion 
As noted by the Nobel Prize laureate Dr. S. Brenner (2002) “…choosing the right organism 
for one’s research is as important as finding the right problems to work on…”  In this 
regard, human peripheral blood lymphocytes and Drosophila melanogaster as model system 
are well validated and permit totally controlled experiments, are relatively low cost and ease 
to use, but most importantly, they resemble neuronal cells and clinical manifestation from 
PD patients, respectively. As any other model (e.g. animal or human tissue and cell lines), 
their limitation is your removal from the reality of the whole, integrated physiologic system. 
Despite this drawback, it turns out that their use in complex biologic investigations such as 
the one presented in this chapter, introduce lymphocytes and Drosophila as a unique 
opportunity to integrate oxidative stress, cell death, cell survival signalling and therapeutic 
pathways signalling in a single-cell and organism model.  
Our present data support the notion that Drosophila melanogaster might be a suitable model 
to study genetic, environmental and nutritional factors as causal and/or modulators in the 
development of PD. Most importantly, according to our model, we have demonstrated for 
the first time that acute cannabinoids or chronic polyphenols exposure as potential 
therapeutic compounds in the treatment of PD.  
These findings altogether open new avenues for the screening, testing, monitoring and 
development of novel antioxidant drugs against oxidative stress stimuli. Furthermore, based 
on our present findings, we propose that a combined therapy with antioxidant and high 
energetic agents should provide to pre-clinical genetically individuals at risk to suffer PD a 
means to delay or to prevent motor symptoms and/or frank PD-ARJP disorders, as those 
encounter in Antioquia, Colombia (Pineda-Trujillo  et al., 2001, 2006, 2009). These data may 
contribute to a better understanding of the inherent nutritional status, genetic predisposition 
and environmental agents as causative factors of PD. However, further studies are needed 
to fully determine target selection and validation, pharmacology, measurement of efficacy 
 
www.intechopen.com
 Mechanisms in Parkinson’s Disease – Models and Treatments 
 
426 
 
 
 
Fig. 10. Survival (A) and locomotor activity (B) of Drosophila melanogaster in absence (0, 
gray bar) or presence of paraquat (1mM) alone (black bar) or in combination of 
polyphenols (epicathecin (EC, 0.1 mM, red bar) or epigallocathecin gallete, EGCG gallate 
(0.1 mM, blue bar) in 1% glucose. Female flies (n= 50 per treatment) were treated as 
described in Materials and Methods section. The graphs show that the proportion of survival 
and climbing performance dramatically increased in flies exposed to polyphenols compared 
to PQ treatment alone.  Statistical comparisons between treated flies with PQ and 
polyphenols and PQ alone showed (A) a P<0.001 by log-rank test and (B) a P<0.05 by 2 test. 
Ortega-Arellano et al., 2011. Reproduced with permission from Elsevier.  
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(Kieburtz & Ravina, 2007) and bioavailability (D'Archivio et al., 2010) of potential 
antioxidant molecules, particularly cannabinoids and polyphenols, before one can envision 
a preventive and effective neuroprotectant therapy against PD.  
4. Acknowledgements 
This work was supported by Colciencias grants #1115-343-19119 & #1115-408-20504; 
Programa Jovenes Investigadores from Colciencias #8790-018-2011; “Proyecto 
Investigaciones Enfermedades Neurodegenerativas“ grants #8780, and “Programa de 
Sostenibilidad grants 2007/2008/2009/2010” to CV-P and MJ-Del-Rio. 
5. References 
Aleyasin, H., Cregan, SP., Lyirhiaro, G., O'Hare, MJ., Callaghan, SM., Slack, RS. & Park, DS. 
(2004). Nuclear factor-(kappa)B modulates the p53 response in neurons exposed to 
DNA damage, J Neurosci 24: 2963-2973. 
Alves, G., Forsaa, EB., Pedersen, KF., Dreetz-Gjerstad, M. & Larsen, JP. (2008). Epidemiology 
of Parkinson's disease, J Neurol 255 Suppl 5:18-32.  
Amenta, F., Bronzetti, E., Felici, L., Ricci, A. & Tayebati, SK. (1999). Dopamine D2-like 
receptors on human peripheral blood lymphocytes: a radioligand binding assay 
and immunocytochemical study, J Auton Pharmacol 19:151-159. 
Amenta, F., Bronzetti, E., Cantalamessa, F., El-Assouad, D., Felici, L., Ricci, A. & Tayebati, 
SK. (2001). Identification of dopamine plasma membrane and vesicular transporters 
in human peripheral blood lymphocytes, J Neuroimmunol 117 (1-2):133-142. 
Asanuma, M., Miyazaki, I., Diaz-Corrales, FJ. & Ogawa, N. (2004). Quinone formation as 
dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic 
Parkinson's disease and neurotoxin-induced parkinsonism, Acta Med Okayama 58: 
221-233.  
Avila-Gomez, I.C., Velez-Pardo, C. & Jimenez-Del-Rio, M. (2010). Effects of insulin-like 
growth factor-1 on rotenone-induced apoptosis in lymphocyte cells, Basic Clin 
Pharmacol Toxicol 106(1): 53-61.  
Bayersdorfer, F., Voigt, A., Schneuwly, S. & Botella, JA. (2010). Dopamine-dependent 
neurodegeneration in Drosophila models of familial and sporadic Parkinson's 
disease, Neurobiol Dis 40(1):113-119. 
Betarbet, R; Sherer, TB & Greenamyre, JT. (2005). Ubiquitin-proteasome system and 
Parkinson’s disease, Exp Neurol 191 Suppl 1: S17-S27.  
Battisti, C., Formichi, P., Radi, E. & Federico, A. (2008). Oxidative-stress-induced apoptosis 
in PBLs of two patients with Parkinson disease secondary to alpha-synuclein 
mutation, J Neurol Sci 267(1-2):120-124. 
Bernstein, AI., Garrison, SP., Zambetti, GP. & O'Malley, KL. (2011). 6-OHDA generated ROS 
induces DNA damage and p53- and PUMA-dependent cell death, Mol Neurodegener 
6(1):2.  
Bonilla, E., Medina-Leendertz, S., Villalobos, V., Molero, L. & Bohórquez, A. (2006). 
Paraquat-induced oxidative stress in drosophila melanogaster: effects of melatonin, 
glutathione, serotonin, minocycline, lipoic acid and ascorbic acid, Neurochem Res 
31(12):1425-1432. 
www.intechopen.com
 Mechanisms in Parkinson’s Disease – Models and Treatments 
 
428 
Botella, JA., Bayersdorfer, F., Gmeiner, F. & Schneuwly, S. (2009). Modelling Parkinson's 
disease in Drosophila, Neuromolecular Med 11(4):268-280. 
Bove, J., Prou, D., Perier, C. & Przedborski, S. (2005). Toxin-induced Models of Parkinson’ 
disease, NeuroRx 2:484-494. 
Blum, D., Torch, S., Lambeng, N., Nissou, M., Benabid, AL., Sadoul, R. & Verna, JM. (2001). 
Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and 
MPTP: contribution to the apoptotic theory in Parkinson's disease, Prog Neurobiol 
65:135-172.  
Brenner, S. (2002). Nature’s gift to science. Nobel lecture, December 8, (www.nobelprize.com).  
Büeler, H. (2010). Mitochondrial dynamics, cell death and the pathogenesis of Parkinson's 
disease, Apoptosis 15(11):1336-1353. 
Calopa, M., Bas, J., Callén, A. &, Mestre, M. (2010). Apoptosis of peripheral blood 
lymphocytes in Parkinson patients, Neurobiol Dis 38(1):1-7.  
Carrillo-Vico, A., Calvo, JR., Abreu, P., Lardone, PJ., Garcia-Maurino, S., Reiter, RJ. & 
Guerrero, JM. (2004). Evidence of melatonin synthesis by human lymphocytes and 
its physiological significance: possible role as intracrine, autocrine, and/or 
paracrine substance, FASEB J 18: 537-539. 
Cocheme, HM. & Murphy, MP. (2008). Complex I is the major site of mitochondrial 
superoxide production by paraquat, J Biol Chem 283: 1786–1798. 
Cookson, MR. (2010). Unravelling the role of defective genes, Prog Brain Res 183:43-57. 
Coulom, H. & Birman, S. (2004). Chronic exposure to rotenone models sporadic Parkinson’s 
disease in Drosophila melanogaster, J Neurosci 24:10993–10998. 
Chaudhuri, A., Bowling, K., Funderburk, C., Lawal, H., Inamdar, A., Wang, Z. & O’Donnell, 
JM. (2007). Interaction of genetic and environmental factors in a Drosophila 
parkinsonism model, J Neurosci 27:2457–2467. 
Chen, Y. & Buck, J. (2000). Cannabinoids protect cells from oxidative cell death: a receptor-
independent mechanism, J Pharmacol Exp Ther 293: 807-812. 
Chen, H., O'Reilly, E., McCullough, ML., Rodriguez, C., Schwarzschild, MA., Calle, EE., 
Thun, MJ. & Ascherio, A.  (2007). Consumption of dairy products and risk of 
Parkinson's disease, Am J Epidemiol  165(9):998-1006. 
Choi, WS., Abel, G., Klintworth, H., Flavell, RA. & Xia, Z. (2010). JNK3 mediates paraquat- 
and rotenone-induced dopaminergic neuron death, J Neuropathol Exp Neurol 
69(5):511-520. 
Chowdhury, I., Tharakan, B. & Bhat, GK. Caspases- an update, Comp Biochem Physiol B 
Biochem Mol Biol 2008;151(1):10-27.  
Cuervo, AM., Wong, ES. & Martinez-Vicente, M. (2010). Protein degradation, aggregation, 
and misfolding, Mov Disord 25 Suppl 1:S49-S54. 
D'Archivio, M., Filesi, C., Di Benedetto, R., Gargiulo, R., Giovannini, C. & Masella, R.  (2007). 
Polyphenols, dietary sources and bioavailability, Ann Ist Super Sanita 43(4):348-361. 
D'Archivio, M., Filesi, C., Varì, R., Scazzocchio, B. & Masella R. (2010). Bioavailability of the 
polyphenols: status and controversies, Int J Mol Sci 11(4):1321-1342. 
Demuth, DG. & Molleman, A. (2006). Cannabinoid signalling, Life Sci 78: 549-563.  
Dexter, DT., Wells, FR., Lees, AJ., Agid, F., Agid, Y., Jenner, P. & Marsden, CD. (1989). 
Increased nigral iron content and alterations in other metal ions occurring in brain 
in Parkinson's disease, J Neurochem 52:1830-1836.  
www.intechopen.com
Human Lymphocytes and Drosophila melanogaster 
as Model System to Study Oxidative Stress in Parkinson's Disease 
 
429 
Dick, FD., De Palma, G., Ahmadi, A., Scott, NW., Prescott, GJ., Bennett, J., Semple, S., Dick, 
S., Counsell, C., Mozzoni, P., Haites, N., Wettinger, SB., Mutti, A., Otelea, M., 
Seaton, A., Soderkvist, P., Felice A, & Geoparkinson study group. (2007). 
Environmental risk factors for Parkinson’s disease and parkinsonism: the 
Geoparkinson study, Occup Environ Med 64:666–672. 
Dorsey, ER., Constantinescu, R., Thompson, JP., Biglan, KM., Holloway, RG., Kieburtz, K., 
Marshall, FJ., Ravina, BM., Schifitto, G., Siderowf, A. & Tanner CM. (2007). 
Projected number of people with Parkinson disease in the most populous nations, 
2005 through 2030, Neurology 68(5):384-386. 
Elsohly, MA. & Slade, D. (2005). Chemical constituents of marijuana: the complex mixture of 
natural cannabinoids, Life Sci 78: 539-548. 
Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A. & Nagata, S. (1998). A 
caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor 
ICAD. Nature 391: 43-50. Erratum in: Nature 1998; 393:396. 
Evans, JR. & Barker, RA. (2008). Neurotrophic factors as a therapeutic target for Parkinson's 
disease, Expert Opin Ther Targets 12(4):437-447.  
Fahn, S. & Cohen, G. (1992). The oxidant stress hypothesis in Parkinson’s disease: evidence 
supporting it, Ann Neurol 32: 804-812.  
Faraj, BA., Olkowski, ZL. & Jackson, RT. (1991). Binding of [3H]-dopamine to human 
lymphocytes: possible relationship to neurotransmitter uptake sites, Pharmacology 
42:135-141.  
Faust, K., Gehrke, S., Yang, Y., Yang, L., Beal, MF. & Lu, B. (2009). Neuroprotective effects of 
compounds with antioxidant and anti-inflammatory properties in a Drosophila 
model of Parkinson's disease, BMC Neurosci 10:109. 
Feany, MB. & Bender, WW. (2000). A Drosophila model of Parkinson’s disease, Nature 
404:394–398. 
Feng, J., Tamaskovic, R., Yang, Z., Brazil, DP., Merlo, A., Hes, D. & Hemmings, BA. (2004). 
Stabilization of Mdm2 via decreased ubiquitination is mediated by protein 
Kinase/Akt-dependent phosphorylation. J Biol Chem 279: 35510-35517. 
Forno, LS. (1996). Neuropathology of Parkinson's disease, J Neuropathol Exp Neurol 55:259-
272.  
García-Arencibia, M., García, C. & Fernández-Ruiz, J. (2009). Cannabinoids and Parkinson's 
disease, CNS Neurol Disord Drug Targets 8(6):432-439.  
Gomez Del Pulgar, T., Velasco, G. & Guzman, M. (2000). The CB 1 cannabinoid receptor is 
coupled to the activation of protein kinase B/Akt, Biochem J 347: 369-373. 
Gomez Del Pulgar, T., de Ceballos, ML., Guzman, M. & Velasco, G. (2002). Cannabinoids 
protect astrocytes from ceramide-induced apoptosis through the 
phosphatidylinositol 3-kinase/protein kinase B pathway, J Biol Chem 277: 36527-
36533.  
Guo, M. (2010). What have we learned from Drosophila models of Parkinson's disease? Prog 
Brain Res 184:3-16.  
Griffiths, PD., Dobson, BR., Jones, GR. & Clarke, DT. (1999). Iron in the basal ganglia in 
Parkinson's disease. An in vitro study using extended X-ray absorption fine 
structure and cryo-electron microscopy, Brain 122 (Pt 4):667-673.  
www.intechopen.com
 Mechanisms in Parkinson’s Disease – Models and Treatments 
 
430 
Halenbeck, R., MacDonald, H., Roulston, A., Chen, TT., Conroy, L. & Williams, LT. (1998). 
CPAN, a human nuclease regulated by the caspase-sensitive inhibitor DFF45, Curr 
Biol 8: 537-540. 
Hampson, AJ., Grimaldi, M., Axelrod, J. & Wink, D. (1998). Cannabidiol and (-) Delta9-
tetrahydrocannabinol are neuroprotective antioxidants, Proc Natl Acad Sci USA 95: 
8268-8273. 
Hardy, J. (2010). Genetic analysis of pathways to Parkinson disease, Neuron 68(2):201-206. 
Haywood, A.F.M., Saunders, LD. & Staveley, BE. (2002). Dopa decarboxylase (Ddc)-GAL4 
dramatically reduces life span, Dros Inf Serv 85: 42-45. 
Heck, S., Lezoualc’h, F., Engert, S. & Behl, C. (1999). Insulin-like growth factor-1-mediated 
neuroprotection against oxidative stress is associated with activation of nuclear 
factor κB, J Biol Chem 274:9828–9835. 
Herrup, K., Neve, R., Ackerman, SL & Copani, A. (2004). Divide and die: cell cycle events as 
triggers of nerve cell death, J Neurosci 24:9232-9239.   
Hirth, F. (2010). Drosophila melanogaster in the study of human neurodegeneration, CNS 
Neurol Disord Drug Targets 9(4):504-523. 
Imai, Y., Soda, M. & Takahashi, R. (2000). Parkin suppresses unfolded protein stress-induced 
cell death through its E3 ubiquitin-protein ligase activity, J Biol Chem 275: 35661-
35664. 
Jankovic, J. (2008). Parkinson's disease: clinical features and diagnosis, J Neurol Neurosurg 
Psychiatry 79(4):368-376.  
Jenner, P. & Olanow, W. (1996). Oxidative stress and the pathogenesis of Parkinson´s 
disease. Neurology 47 (Suppl. 3):S161-S170.  
Jenner, P. & Olanow, CW. (1998). Understanding cell death in Parkinson's disease. Ann 
Neurol. 44 (3 Suppl 1):S72-S84.   
Jiang, H., Ren, Y., Zhao, J. & Feng, J. (2004). Parkin protects human dopaminergic 
neuroblastoma cells against dopamine-induced apoptosis, Human Mol Genet 
13:1745–1754.  
Jimenez-Del-Rio, M. & Velez-Pardo, C. (2000). Molecular mechanism of monoamine toxicity 
in Parkinson’s disease: A hypothetical cell death model, Medic Hypotheses  54: 269-
274. 
Jimenez-Del-Rio, M & Velez-Pardo, C. (2001). 17ǃ-Estradiol protects lymphocytes against 
dopamine and iron-induced apoptosis by a genomic-independent mechanism 
Implication in Parkinson’s disease, Gen Pharmacol 35: 1– 9. 
Jimenez-Del-Rio, M. & Velez-Pardo, C. (2002). Monoamine neurotoxin-induced apoptosis in 
lymphocytes by a common mechanism: involvement of hydrogen peroxide (H2O2), 
caspase-3, and nuclear factor kappa-B (NF-κB), p53, c-Jun transcription factor, 
Biochem Pharmacol 63: 677-688.  
Jimenez-Del-Rio, M., Moreno, S., Garcia-Ospina, G., Buritica, O., Uribe, CS., Lopera, F. & 
Velez-Pardo, C. (2004). Autosomal recessive juvenile parkinsonism Cys212Tyr 
mutation in parkin renders lymphocytes susceptible to dopamine and iron-
mediated apoptosis, Mov Disord 19: 324-330.  
Jimenez-Del-Rio, M. & Velez-Pardo, C. (2004a). The hydrogen peroxide and its importance 
in the Alzheimer’s and Parkinson’s disease, Current Medical Chemistry- Central 
Nervous System Agents 4: 279-285. 
www.intechopen.com
Human Lymphocytes and Drosophila melanogaster 
as Model System to Study Oxidative Stress in Parkinson's Disease 
 
431 
Jimenez-Del-Rio, M. & Velez-Pardo, C. (2004b). Transition metals-induced apoptosis in 
lymphocytes via hydroxyl radical generation, mitochondria dysfunction and 
caspase-3 activation: an in vitro model for neurodegeneration, Arch Medic Res 
35:185-193.   
Jimenez-Del-Rio, M. & Velez-Pardo, C. (2006). Insulin-like growth factor-1 prevents Aǃ[25-35] 
/(H2O2)-induced apoptosis in lymphocytes by reciprocal NF-κB activation and p53 
inhibition  via PI3K-dependent pathway. Growth Factors 24: 67-78. 
Jimenez-Del-Rio, M. & Velez-Pardo, C. (2008). Paraquat induces apoptosis in human 
lymphocytes: Protective and rescue effects of glucose, cannabinoids and Insulin-
like growth factor-1, Growth Factors 26(1): 49-60.    
Jimenez-Del-Rio, M., Daza-Restrepo, A. & Velez-Pardo, C. (2008). The cannabinoid CP55, 
940 prolongs survival and improves locomotor activity in Drosophila melanogaster 
against paraquat: implications in Parkinson’s disease, Neurosci Res 61:404–411. 
Jimenez-Del-Rio, M., Guzman-Martinez, C. & Velez-Pardo, C. (2010). The effects of 
polyphenols on survival and locomotor activity in Drosophila melanogaster 
exposed to iron and paraquat, Neurochem Res 35(2):227-238. 
Jones, DC. & Miller, GW. (2008). The effects of environmental neurotoxicants on the 
dopaminergic system: a possible role in drug addiction, Biochem Pharmacol 76:569–
581.  
Kairisalo, M., Korhonen, L., Blomgren, K. & Lindholm, D. (2007). X-linked inhibitor of 
apoptosis protein increases mitochondrial antioxidants through NF-kappaB 
activation, Biochem Biophys Res Commun 364(1):138-144.  
Kane, LP., Shapiro, VS., Stokoe, D. & Weiss, A. (1999). Induction of NF-kappaB by the 
Akt/PKB kinase. Curr Biol. 9: 601-604. 
Kawashima, K. & Fujii, T. (2004). Expression of non-neuronal acetylcholine in lymphocytes 
and its contribution to the regulation to the regulation of immune function, 
Frontiers Biosci 9:2063-2085.  
Kerr, JFR., Wyllie, AH. & Currie, AR. (1972). Apoptosis: a basic biological phenomenon with 
wide ranging implications in tissue kinetics, Br J Cancer 26: 239-257. 
Kerr, JFR., Gobe, GC., Winterford, CM. & Harmon, BV. Anatomical methods in cell death. 
In: Schwartz, LM.  & Osborne, BA; editors. Methods in cell biology: cell death. New 
York: Academic Press; 1995; pp. 1–27. 
Kim, SH., Won, SJ., Mao, XO., Jin, K. & Greenberg, DA. (2005). Involvement of protein 
kinase A in cannabinoid receptor-mediated protection from oxidative neuronal 
injury, J Pharmacol Exp Ther 313: 88-94. 
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, 
M., Mizuno, Y. & Shimizu, N. (1998). Mutations in the parkin gene cause autosomal 
recessive juvenile parkinsonism, Nature 392:605-608. 
Kooijman, R., Willems, M., DeCarla, HJC., Rijkers, GT., Schuurmans, ALG., Van Buul-
Offers, SC., Heijnen, CJ. & Zegers, BJM. (1992). Expression of type I insulin-like 
growth factor receptors on human peripheral blood mononuclear cells, Endocrinol 
131: 2244-2250. 
Kutuk, O. & Basaga, H. (2003). Aspirin prevents apoptosis and NFkappaB activation 
induced by H2O2 in HeLa cells, Free Radic Res 37:1267–1276. 
www.intechopen.com
 Mechanisms in Parkinson’s Disease – Models and Treatments 
 
432 
Kaplan, BL., Rockwell, CE. & Kaminski, NE. (2003).  Evidence for cannabinoid receptor-
dependent and -independent mechanisms of action in leukocytes, J Pharmacol Exp 
Ther 306(3):1077-1085.  
Kieburtz, K. & Ravina, B. (2007). Why hasn't neuroprotection worked in Parkinson's 
disease? Nat Clin Pract Neurol 3(5):240-241.  
Kriesberg, N. (2011). Animals as models. 
 (http://ori.dhhs.gov/education/products/ncstate/models.htm, available in April, 
2011). 
Klegeris, A., Bissonnette, CJ. & McGeer, PL. (2003). Reduction of human monocytic cell 
neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 
receptor. Br J Pharmacol. 139: 775-786.  
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, ES., Baehrecke, EH., 
Blagosklonny, MV., El-Deiry, WS., Golstein, P., Green, DR., Hengartner, M., 
Knight, RA., Kumar, S., Lipton, SA., Malorni, W., Nuñez, G., Peter, ME., Tschopp, 
J., Yuan, J., Piacentini, M., Zhivotovsky, B., Melino, G. & Nomenclature Committee 
on Cell Death 2009. (2009. Classification of cell death: recommendations of the 
Nomenclature Committee on Cell Death 2009, Cell Death Differ 16(1):3-11.  
Levy, OA., Malagelada, C. & Greene, LA. (2009). Cell death pathways in Parkinson's 
disease: proximal triggers, distal effectors, and final steps, Apoptosis 14(4):478-500. 
Liang, ZQ., Li, YL., Zhao, XL., Han, R., Wang, XX., Wang, Y., Chase, TN., Bennett, MC. & 
Qin, ZH. (2007). NF-B contributes to 6-hydroxydopamine-induced apoptosis of 
nigral dopaminergic neurons through p53. Brain Res 1145:190-203.  
Li, LY., Zhao, XL., Fei, XF., Gu, ZL., Qin, ZH. & Liang, ZQ. (2008). Bilobalide inhibits 6-
OHDA-induced activation of NF-kappaB and loss of dopaminergic neurons in rat 
substantia nigra, Acta Pharmacol Sin 29(5):539-547. 
Lin, TK., Liou, CW., Chen, SD., Chuang, YC., Tiao, MM., Wang, PW., Chen, JB. & Chuang, 
JH. (2009). Mitochondrial dysfunction and biogenesis in the pathogenesis of 
Parkinson's disease, Chang Gung Med J 32(6):589-599. 
Liu, X., Zou, H., Slaughter, C. & Wang, X. (1997). DFF, a heterodimeric protein that 
functions downstream of caspase-3 to trigger DNA fragmentation during 
apoptosis, Cell. 89:175-184. 
Logroscino, G., Gao, X., Chen, H., Wing A. & Ascherio, A. (2008). Dietary iron intake and 
risk of Parkinson's disease, Am J Epidemiol 168(12):1381-1388. 
Lombardi, G., Dianzani, C., Miglio, G., Canonico, PL. & Fantozzi, R. (2001). Characterization 
of ionotropic glutamate receptors in human lymphocytes, Br J Pharmacol 133: 936-
944. 
Lombardi, G., Miglio, G., Dianzani, C., Mesturini, R., Varsaldi, F., Chiocchetti, A., Dianzani, 
U., Fantozzi, R. (2004). Glutamate modulation of human lymphocyte growth: in 
vitro studies, Biochem Biophys Res Commun. 28; 318: 496-502. 
Lu, Y. (2005). p53: a heavily dictated dictator of life and death, Curr Opin Genet Dev 15: 27-33. 
Lu, B. (2009). Recent advances in using Drosophila to model neurodegenerative diseases, 
Apoptosis 14(8):1008-1020.  
Maciver, NJ., Jacobs, SR., Wieman, HL., Wofford, JA., Coloff, JL. & Rathmell, JC. (2008). 
Glucose metabolism in lymphocytes is a regulated process with significant effects 
on immune cell function and survival, J. Leukoc. Biol. 84,949-957. 
www.intechopen.com
Human Lymphocytes and Drosophila melanogaster 
as Model System to Study Oxidative Stress in Parkinson's Disease 
 
433 
Manolescu, AR., Witkowska, K., Kinnaird, A., Cessford T., Cheeseman, C. (2007). Facilitated 
hexose transporters: new perspectives on form and function, Physiology (Bethesda) 
22, 234-240. 
Mao, Z. & Davis, RL. (2009). Eight different types of dopaminergic neurons innervate the 
Drosophila mushroom body neuropil: anatomical and physiological heterogeneity, 
Front Neural Circuits 3:5. 
Marazziti, D., Consoli, G., Masala, I., Catena Dell'Osso, M. & Baroni, S. (2010). Latest 
advancements on serotonin and dopamine transporters in lymphocytes, Mini Rev 
Med Chem 10(1):32-40.  
Marini, M., Frabetti, F., Canaider, S., Dini, L., Falcieri, E. & Poirier, GG. (2001). Modulation 
of caspase-3 activity by zinc ions and by the cell redox state, Exp Cell Res 266:323-
332. 
Marino, F., Cosentino, M., Bombelli, R., Ferrari, M., Lecchini, S. & Frigo, G. (1999). 
Endogenous catecholamine synthesis, metabolism, storage, and uptake in human 
peripheral blood mononuclear cells, Exp Hematol 27:489-495. 
Marsicano, G., Moosmann, B., Hermann, H., Lutz, B. & Behl, C. (2002). Neuroprotective 
properties of cannabinoids against oxidative stress: role of the cannabinoid receptor 
CB1, J Neurochem  80: 448-456. 
Massoud, TF., Hademenos, GJ., Young, WL., Gao, E., Pile-Spellman, J., Viñuela, F. (1998). 
Principles and philosophy of modeling in biomedical research,FASEB J 12(3):275-
285.  
Matsuda, LA., Lolait, SJ., Brownstein, M., Young, A. & Bonner, TI. (1990). Structure of a 
cannabinoid receptor and functional expression of the cloned cDNA, Nature 346: 
561-564. 
Melidou, M., Riganakos, K. & Galaris, D. (2005). Protection against nuclear DNA damage 
offered by flavonoids in cells exposed to hydrogen peroxide: the role of iron 
chelation, Free Radic Biol Med 39:1591–1600. 
Miglio, G., Varsaldi, F., Dianzani, C., Fantozzi, R. & Lombardi, G. (2005). Stimulation of 
group I metabotropic glutamate receptors evokes calcium signals and c-jun and c-
fos gene expression in human T cells, Biochem Pharmacol 70:189-199.   
Migliore, L., Petrozzi, L., Lucetti, C., Gambaccini, G., Bernardini, S., Scarpato, R., Trippi, F., 
Barale, R., Frenzilli, G., Rodilla, V. & Bonuccelli, U. (2002). Oxidative damage and 
cytogenetic analysis in leukocytes of Parkinson's disease patients, Neurology 58: 
1809-1815.   
Miyashita, T. & Reed, JC. (1995). Tumor suppressor p53 is a direct transcriptional activator 
of the human bax gene, Cell 80: 293–299. 
Molina-Holgado, E., Vela, J.M., Arevalo-Martin, A., Almazan, G., Molina-Holgado, F., 
Borrell, J. & Guaza, C. (2002). Cannabionoids promote oligodendrocyte progenitor 
survival: involvement of cannabinoid receptors and phospahatidylinositol-3 
kinase/Akt signaling, J Neurosc 22: 9742-9753.  
Munro, S., Thomas, KL. & Abu-Shaar, M. (1993). Molecular characterization of a peripheral 
receptor for cannabinoids, Nature 365: 61-65. 
McKenna, F., McLaughlin, PJ., Lewis, BJ., Sibbring, GC., Cummerson, JA., Bowen-Jones, D. 
& Moots, RJ. (2002).  Dopamine receptor expression on human T- and B-
lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric 
study, J Neuroimmunol. 132 (1-2):34-40. 
www.intechopen.com
 Mechanisms in Parkinson’s Disease – Models and Treatments 
 
434 
Nagayama, T., Sinor, AD., Simon, RP., Chen, J., Graham, SH., Jin, K. & Greenberg, DA. 
(1999). Cannabinoids and neuroprotection in global and focal cerebral ischemia and 
in neuronal cultures, J Neurosci 19: 2987-2995. 
Ogawara, Y., Kishishita, S., Obata, T., Isazawa, Y., Suzuki, T., Tanaka, K., Masuyama, N. & 
Gotoh, Y. (2002). Akt enhances Mdm2-mediated Ubiquitination and degradation of 
p53, J Biol Chem 277: 21843-21850.  
Ortega-Arellano, HF., Jimenez-Del-Rio, M. & Velez-Pardo, C. (2011). Life span and 
locomotor activity modification by glucose and polyphenols in Drosophila 
melanogaster chronically exposed to oxidative stress-stimuli: Implications in 
Parkinson's disease, Neurochem Res 36: 1073-1086. 
Padgett, LW. (2005). Recent developments cannabinoid ligands, Life Sci 77: 1767-1798.  
Pendleton, RG., Parvez, F., Sayed, M., Hillman, R. (2002a). Effects of pharmacological agents 
upon a transgenic model of Parkinson’s disease in Drosophila melanogaster, J 
Pharmacol Exp Ther 300:91–96. 
Pendleton, RG., Rasheed, A., Sardina, T., Tully, T. & Hillman, R. (2002b). Effects of tyrosine 
hydroxylase mutants on locomotor activity in Drosophila: a study in functional 
genomics, Behav Genet 32: 89–94. 
Park, J., Kim, Y., Chung, J. (2009).  Mitochondrial dysfunction and Parkinson's disease genes: 
insights from Drosophila, Dis Model Mech 2(7-8):336-340.  
Pazos, MR., Nunez, E., Benito, C., Tolon, RM. & Romero, J. (2005). Functional neuroanatomy 
of the endocannabinoid system, Pharmacol Biochem Behav 81:239-247. 
Perron, NR. & Brumaghim, JL. (2009). A review of the antioxidant mechanisms of 
polyphenol compounds related to iron binding, Cell Biochem Biophys 53:75–100. 
Phelps, CB. & Brand, AH. (1998). Ectopic gene expression in Drosophila using GAL4 system, 
Methods 14(4):367-379.  
Piatkiewicz, P., Czech, A. & Tatoń, J. (2007). Glucose transport in human peripheral blood 
lymphocytes influenced by type 2 diabetes mellitus, Arch. Immunol. Ther. Exp. 
(Warsz) 55,119-126. 
Pineda-Trujillo, N., Carvajal-Carmona, LG., Buritica, O., Moreno, S., Uribe, C., Pineda, D., 
Toro, M., Garcia, F., Arias, W., Bedoya, G., Lopera, F. & Ruiz-Linares, A. (2001). A 
novel Cys212Tyr founder mutation in parkin and allelic heterogeneity of juvenile 
Parkinsonism in a population from North West Colombia, Neurosci Lett 298: 87-90. 
Pineda-Trujillo, N., Apergi, M., Moreno, S., Arias, W., Lesage, S., Franco, A., Sepulveda-
Falla, D., Cano, D., Buritica, O., Pineda, D., Uribe, CS., de Yebenes, JG., Lees, AJ., 
Brice, A., Bedoya, G., Lopera, F. & Ruiz-Linares, A. (2006). A genetic cluster of early 
onset Parkinson's disease in a Colombian population, Am J Med Genet B 
Neuropsychiatr Genet 141B(8):885-888. 
Pineda-Trujillo, N., Dulcey-Cepeda, A., Arias-Pérez, W., Moreno-Masmela, S., Saldarriaga-
Henao, A., Sepúlveda-Falla, D., Bedoya-Berrío, G., Lopera-Restrepo F. & Ruiz-
Linares, A. (2009). Una mutación en el gen PARK2 causa enfermedad de Parkinson 
juvenil en una extensa familia colombiana, IATREIA 22( 2): 122-131.   
Polymeropoulos, MH., Lavedan, C., Leroy, E., Ide, SE., Dehejia, A., Dutra, A., Pike, B., Root, 
H., Rubenstein, J., Boyer, R., Stenroos, ES., Chandrasekharappa, S., Athanassiadou, 
A., Papapetropoulos, T., Johnson, WG., Lazzarini, AM., Duvoisin, RC., Di Iorio G., 
Golbe LI. & Nussbaum, RL. (1997). Mutation in the alpha-synuclein gene identified 
in families with Parkinson's disease, Science 27; 276:2045-2047. 
www.intechopen.com
Human Lymphocytes and Drosophila melanogaster 
as Model System to Study Oxidative Stress in Parkinson's Disease 
 
435 
Prabhakaran, K., Ghosh, D., Chapman, GD. & Gunasekar, PG. (2008). Molecular mechanism 
of manganese exposure-induced dopaminergic toxicity, Brain Res Bull 76(4):361-367.  
Pradilla, AG., Vesga, ABE., León-Sarmiento, FE; GENECO. (2003). [National 
neuroepidemiological study in Colombia (EPINEURO)], Rev Panam Salud Publica 
14(2):104-11. 
Prasad, S., Ravindran, J. & Aggarwal, BB. (2010). NF-kappaB and cancer: how intimate is 
this relationship, Mol Cell Biochem 336(1-2):25-37.  
Przedborski, S. (2005). Pathogenesis of nigral cell death in Parkinson's disease, Parkinsonism 
Relat Disord 11 Suppl 1:S3-S7.  
Prigione, A., Isaias, IU., Galbussera, A., Brighina, L., Begni, B., Andreoni, S., Pezzoli, G., 
Antonini, A., Ferrarese, C. (2009). Increased oxidative stress in lymphocytes from 
untreated Parkinson's disease patients, Parkinsonism Relat Disord 15(4):327-328. 
Qin, ZH., Tao, LY. & Chen, X. (2007). Dual roles of NF-kappaB in cell survival and 
implications of NF-kappaB inhibitors in neuroprotective therapy, Acta Pharmacol 
Sin 28(12):1859-72.   
Quesada, A., Lee, BY. & Micevych, PE. (2008). PI3 kinase/Akt activation mediates estrogen 
and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of 
Parkinson's disease, Dev Neurobiol 68(5):632-644. 
Ramassamy, C. (2006). Emerging role of polyphenolic compounds in the treatment of 
neurodegenerative diseases: a review of their intracellular targets, Eur J Pharmacol 
545:51–64. 
Ricci, A. & Amenta, F. (1994). Dopamine D5 receptors in human peripheral blood 
lymphocytes: a radioligand binding study, J Neuroimmunol 53: 1-7.  
Ricci, A., Veglio, F. & Amenta, F. (1995). Radioligand binding characterization of putative 
dopamine D3 receptor in human peripheral blood lymphocytes with {3H} 7OH-
DPAT, J Neuroimmunol 58: 139-144. 
Ricci, A., Bronzetti, E., Felici, L., Tayebati, SK. & Amenta, F. (1997). Dopamine D4 receptor in 
human peripheral blood lymphocytes: a radioligand binding assay study, Neurosci 
Lett 229: 130-134.  
Riederer, P., Dirr, A., Goetz, M., Sofic, E., Jellinger, K. & Youdim, MB. (1992). Distribution of 
iron in different brain regions and subcellular compartments in Parkinson's disease, 
Ann Neurol 32 Suppl: S101-S104. 
Riemensperger, T., Isabel, G., Coulom, H., Neuser, K., Seugnet, L., Kume, K., Iché-Torres, 
M., Cassar, M., Strauss, R., Preat, T., Hirsh, J. & Birman, S. (2011). Behavioral 
consequences of dopamine deficiency in the Drosophila central nervous system, 
Proc Natl Acad Sci U S A 108(2):834-839. 
Sanchez, MG., Ruiz-Llorente, L., Sanchez, AM. & Diaz-Leviada, I. (2003).  Activation of 
phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid 
receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and 
NGF induction, Cell Signal 15: 851-859.  
Sanchez, JL., Buritica-Henao, O., Pineda Salazar, DA., Ribe, CS. & Palacio-Baena, LG. (2004). 
Prevalence of Parkinson´s disease and Parkinsonism in a Colombian population 
using the capture recapture methods. Int J Neurosci 113:175-182.  
Sanders, VM. (1998). The role of norepinephrine and beta-2 adrenergic receptor stimulation 
in the modulation of Th1, Th2, and B lymphocyte function, Adv Exp Med Biol 
437:269-278. 
www.intechopen.com
 Mechanisms in Parkinson’s Disease – Models and Treatments 
 
436 
Sang, TK., Chang, HY., Lawless, GM., Ratnaparkhi, A., Mee, L., Ackerson, LC., Maidment, 
NT., Krantz, DE. & Jackson, GR. (2007). A Drosophila model of mutant human 
parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and 
dependence on cellular dopamine, J Neurosci 27:981–992. 
Sakahira, H., Enari, M. & Nagata, S. (1998). Cleavage of CAD inhibitor in CAD activation 
and DNA degradation during apoptosis, Nature 391: 96-99. 
Sakahira, H., Enari, M., Ohsawa, Y., Uchiyama, Y. & Nagata, S. (1999). Apoptotic nuclear 
morphological change without DNA fragmentation, Curr Biol 9: 543-546.  
Savica, R., Rocca, WA. & Ahlskog, JE. (2010). When does Parkinson disease start? Arch 
Neurol 67(7):798-801. 
Sestili, P., Diamantini, G., Bedini, A., Cerioni, L., Tommasini, I., Tarzia, G. & Cantoni, O. 
(2002). Plant-derived phenolic compounds prevent the DNA single-strand 
breakage and cytotoxicity induced by tertbutylhydroperoxide via an iron-chelating 
mechanism, Biochem J 364(Pt 1):121–128. 
Sian-Hülsmann, J., Mandel, S., Youdim, HMB. & Riederer, P. (2010). The Relevance of iron 
in the pathogenesis of Parkinson's Disease, J Neurochem doi: 10.1111/j.1471-
4159.2010.07132.x. 
Sofic, E., Paulus, W., Jellinger, K., Riederer, P. & Youdim, MB. (1991). Selective increase of 
iron in substantia nigra zona compacta of parkinsonian brains, J Neurochem. 56: 978-
982.  
Shishodia, S. & Aggarwal, BB. (2004). Nuclear factor kB: a friend or a foe in cancer? Biochem 
Pharmacol 68: 1071-1080. 
Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., 
Iwai, K., Chiba, T., Tanaka, K. & Suzuki, T. (2000). Familial Parkinson disease gene 
product, parkin is an ubiquitin-protein ligase, Nat Genet 25:302-305.  
Skaper, SD., Buriani, A., Dal Toso, R., Petrelli, L., Romanello, S., Facci, L. & Leon, A. (1996). 
The Aliamide palmitoylethanolamine and cannabinoids, but not anandamide, are 
protective in a delayed postglutamate paradigm of exocitotoxic death in cerebellar 
granule neurons, Proc Natl Acad Sci USA 93: 3984-3989. 
Stefulj, J., Jernej, B., Cicin-Sain, L., Rinner, I. & Schauenstein K. (2000). mRNA expression of 
serotonin receptors in cells of the immune tissues of the rat, Brain Behav Immun 
14(3):219-224. 
Tan, JM., Wong, ES. & Lim, KL. (2009). Protein misfolding and aggregation in Parkinson's 
disease, Antioxid Redox Signal 11(9):2119-2134. 
Takada, Y., Mukhopadhyay, A., Kundu, GC., Mahabeleshwar, GH., Singh, S. & Aggarwal, 
BB. (2003). Hydrogen peroxide activates NF-kappa B through tyrosine 
hosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for 
the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase, J Biol 
Chem 278: 24233-24241.  
Takanashi, M., Mochizuchi, H., Yokomizo, K., Hattori, N., Mori, H., Yamamura, Y. & 
Mizuno, Y. (2001). Iron accumulation in the substantia nigra of autosomal recessive 
juvenile parkinsonism (ARJP), Parkinsonism Relat Disord 7: 311–314. 
Tanaka, K., Suzuki, T., Chiba, T., Shimura, H., Hattori, N. & Mizuno, Y.  (2001). Parkin is 
linked to the ubiquitin pathway, J Mol Med 79: 482-494. 
www.intechopen.com
Human Lymphocytes and Drosophila melanogaster 
as Model System to Study Oxidative Stress in Parkinson's Disease 
 
437 
Tapson, VF., Schenetzler, B., Pilch, PF., Center, DM. & Berman, JS. (1988). Structural and 
functional characterization of the human T lymphocyte receptor for insulin-like 
growth factor I in vitro, J Clin Invest 82: 950-957.  
Tillakaratne, NJ., Medina-Kauwe, L. & Gibson, KM. (1995). Gamma Aminobutyric acid 
(GABA) metabolism in mammalian neural and non-neural tissues, Comp Biochem 
Physiol A Physiol 112(2):247-263. 
Thakur, GA., Duclos, RI Jr. & Makriyannis, A. (2005). Natural cannabinoids: Templates for 
drug discovery, Life Sci 78: 454-466.   
Tsang, AH. & Chung, KK. (2009). Oxidative and nitrosative stress in Parkinson's disease, 
Biochim Biophys Acta 1792(7):643-650.  
Turu, G. & Hunyady, L. (2010). Signal transduction of the CB1 cannabinoid receptor, J Mol 
Endocrinol 44(2):75-85.  
Van der Stelt, M. & Di Marzo, V. (2005). Cannabinoid receptors and their role in 
neuroprotection, Neuromolecular Med. 7(1-2):37-50. 
Van Sickle, MD., Duncan, M., Kingsley, PJ., Mouihate, A., Urbani, P., Mackie, K., Stella, N., 
Makriyannis, A., Piomelli, D., Davison, JS., Marnett, LJ., Di Marzo, V., Pittman, QJ., 
Patel, KD. & Sharkey, KA. (2005). Identification and functional characterization of 
brainstem cannabinoid CB2 receptors, Science 310:329-332. 
Velez-Pardo, C. & Jimenez-Del-Rio, M. (2006). Avoidance of A[25-35] /(H2O2)-induced 
apoptosis in lymphocytes by the cannabinoid agonists CP55,940 and JWH-015 via 
receptor-independent and PI3K-dependent mechanisms: Role of NF-B and p53, 
Medicinal Chemistry 2: 471-479. 
Velez-Pardo, C., Jimenez-Del-Rio, M., Lores-Arnaiz, S. & Bustamante, J. (2010). Protective 
effects of the synthetic cannabinoids CP55,940 and JWH-015 on rat brain 
mitochondria upon paraquat exposure, Neurochemical Research  35:1323–1332.  
Wang, C., Lu, R., Ouyang, X., Ho, M.W., Chia, W., Yu, F., & Lim, K.L. (2007). Drosophila 
overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration 
and mitochondrial abnormalities, J Neurosci 27:8563–8570. 
White, KE., Humphrey, DM., Hirth, F. (2010). The dopaminergic system in the aging brain 
of Drosophila, Front Neurosci 4:205. 
Wu, H; Lozano, G. (1994). NF-κB activation of p53, J Biol Chem 269: 20067–20074. 
Wyllie, AH. (1980). Glucocorticoid-induced thymocytes apoptosis associated with 
endogenous endonuclease activation, Nature 284: 555-556.   
Wang, C., Lu, R., Ouyang, X., Ho, M.W., Chia, W., Yu, F., & Lim, K.L. (2007). Drosophila 
overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration 
and mitochondrial abnormalities, J Neurosci 27:8563–8570. 
Wang, X. & Michaelis, EK. (2010) Selective neuronal vulnerability to oxidative stress in the 
brain, Front Aging Neurosci 2:12. 
Whitworth, AJ., Wes, PD. & Pallanck, LJ. (2006). Drosophila models pioneer a new approach 
to drug discovery for Parkinson's disease, Drug Discov Today 11(3-4):119-126.  
Whitworth, AJ. (2011). Drosophila models of Parkinson's disease, Adv Genet 73:1-50. 
Xiang, H., Kinoshita, Y., Knudson, CM., Korsmeyer, SJ., Schwartzkroin, PA. & Morrison, RS. 
(1998). Bax involvement in p53-mediated neuronal cell death, J Neurosci 18(4):1363-
1373. 
www.intechopen.com
 Mechanisms in Parkinson’s Disease – Models and Treatments 
 
438 
Xiromerisiou, G., Dardiotis, E., Tsimourtou, V., Kountra, PM., Paterakis, KN., Kapsalaki, 
EZ., Fountas, KN. &  Hadjigeorgiou, GM. (2010). Genetic basis of Parkinson 
disease, Neurosurg Focus 28(1):E7. 
Xu, G. & Shi, Y. (2007). Apoptosis signaling pathways and lymphocyte homeostasis, Cell Res 
17(9):759-771. 
Zaveri, NT. (2006). Green tea and its polyphenolic catechins: medicinal uses in cancer and 
noncancer applications, Life Sci 78:2073–2080.  
Zhang, Y., Dawson, VL. & Dawson, TM. (2001). Parkin: clinical aspects and neurobiology, 
Clin Neurosci Res 1: 467– 482. 
Zhou, C., Huang, Y., Przedborski, S. (2008). Oxidative stress in Parkinson’s disease: a 
mechanism of pathogenic and therapeutic significance, Ann N Y Acad Sci 1147:93–
104. 
www.intechopen.com
Mechanisms in Parkinson's Disease - Models and Treatments
Edited by Dr. Juliana Dushanova
ISBN 978-953-307-876-2
Hard cover, 582 pages
Publisher InTech
Published online 08, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the substantia nigra.
Current PD medications treat symptoms; none halt or retard dopaminergic neuron degeneration. The main
obstacle to developing neuroprotective therapies is a limited understanding of the key molecular mechanisms
that provoke neurodegeneration. The discovery of PD genes has led to the hypothesis that misfolding of
proteins and dysfunction of the ubiquitin-proteasome pathway are pivotal to PD pathogenesis. Previously
implicated culprits in PD neurodegeneration, mitochondrial dysfunction, and oxidative stress may also act in
part by causing the accumulation of misfolded proteins, in addition to producing other deleterious events in
dopaminergic neurons. Neurotoxin-based models have been important in elucidating the molecular cascade of
cell death in dopaminergic neurons. PD models based on the manipulation of PD genes should prove valuable
in elucidating important aspects of the disease, such as selective vulnerability of substantia nigra dopaminergic
neurons to the degenerative process.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Marlene Jimenez-Del-Rio and Carlos Velez-Pardo (2012). Human Lymphocytes and Drosophila melanogaster
as Model System to Study Oxidative Stress in Parkinson's Disease, Mechanisms in Parkinson's Disease -
Models and Treatments, Dr. Juliana Dushanova (Ed.), ISBN: 978-953-307-876-2, InTech, Available from:
http://www.intechopen.com/books/mechanisms-in-parkinson-s-disease-models-and-treatments/human-
lymphocytes-and-drosophila-melanogaster-as-model-system-to-study-oxidative-stress-in-parkinson
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
